Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.70 |
| ▸ | KDR | P35968 | 5/20 | 0.70 |
| ▸ | JAK3 | P52333 | 5/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.70 |
| ▸ | ABL1 | P00519 | 6/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494215 | 1.00 | LCK (0.70) | LCKKDRJAK3MAPK14ABL1 | |
| SCHEMBL5494575 | 0.82 | LCK (1.00) | LCKKDRJAK3MAPK14BRAF | |
| SCHEMBL5489139 | 0.81 | LCK (0.72) | LCKKDRJAK3MAPK14ABL1 | |
| Ammonia Solution, Strong SCHEMBL5496907 | 0.81 | ABL1 (0.62) | LCKKDRJAK3MAPK14ABL1 | |
| SCHEMBL5496775 | 0.80 | ABL1 (0.54) | LCKKDRJAK3MAPK14ABL1 | |
| SCHEMBL3025007 | 0.79 | LCK (0.55) | LCKKDRJAK3MAPK14BRAF | |
| SCHEMBL9938086 | 0.78 | ABL1 (1.00) | ABL1CYP11B1CYP11B2MAP4K1 | |
| SCHEMBL5492816 | 0.78 | LCK (0.72) | LCKKDRJAK3MAPK14BRAF | |
| SCHEMBL14569081 | 0.78 | ABL1 (0.58) | LCKKDRJAK3MAPK14ABL1 | |
| SCHEMBL28019341 | 0.78 | LCK (0.78) | LCKKDRJAK3MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-07-24 | — | — | US | disclosed |
| CN-118176181-A | SARM1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023072026-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-05-04 | — | — | WO | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2008068507-A2 | 2 -PHENYLAMINO, 6- (PYRID-3-YL) QUINAZOLINE DERIVATIVES AS RAF-PROTEIN KINASE INHIBITORS IN CANCER TREATMENT | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, ADRM1, SMN1; SMN2 | LCK 3727/4885KDR 2907/4885JAK3 4829/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KDR 1044/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.